NCTN Genitourinary Cancer Trials Portfolio (Open as of 12/15/2020)

Each far right box includes the NCTN protocol number with a hyperlink to the associated ClinicalTrials.gov webpage. Click on it to view the protocol title and study information.

**Prostate cancer**
- Newly diagnosed, Surgical Tx indicated
  - EA8171
- Localized, Previously untreated, Intermediate risk
  - NRG-GU005
  - NRG-GU007
- Previously untreated, High risk, Non-metastatic
  - NRG-GU009 (PREDICT-RT)
- Previously untreated, Metastatic
  - S1802
  - NRG-GU0002
- Post Prostatectomy, High risk
  - EA8183 (ERADICATE)
- Post Prostatectomy, Undetectable PSA, High risk of metastasis
  - EA8191
- Post Prostatectomy, Biochemical recurrence
  - NRG-GU0008
- Post Prostatectomy, Node positive, M0 disease
  - EA8153 (CHAARTED2)
- Metastatic, Castration-resistant
  - S1802
  - NRG-GU0002
  - EA8183 (ERADICATE)

**Renal cell carcinoma**
- Newly diagnosed, High risk, M0
  - EA8143 (PROSPER RCC)
- TFE/translocation, Unresectable or metastatic
  - AREN1721
- Metastatic, Untreated
  - A031704 (PDIGREE)
- At least two untreated bone metastases
  - A031801 (RadiCal)
- Metastatic, Untreated or treated
  - S1931 (PROBE)

**Urothelial tract/Bladder cancer**
- Non-Muscle invasive
  - BCG-Unresponsive
    - A031803
  - Localized
    - S1806
  - Post bladder resection
  - A031501 (AMBASSADOR)
  - Newly diagnosed, T2-4a,N0/x,M0
  - A031701
  - Any T, N1-2, M0
  - EA8185 (INSPIRE)
  - Locally advanced or metastatic
  - A031901

**Rare GU cancers**
- Metastatic disease
  - A031702

**Penile squamous carcinoma**
- Any T, N1-3, M0
  - EA8134 (InPACT)

**Germ cell cancer**
- Progressive or Recurrent
  - A031102 (TIGER)
NCTN Genitourinary Cancer Trials Portfolio (Open as of 12/15/2020)
Each box below includes the NCTN protocol number with a hyperlink to the associated ClinicalTrials.gov webpage. Click on it to view the protocol title and study information.

Cross-disease trials:

- EAY131 (MATCH)
- S1609 (DART)
### NCTN Genitourinary Cancer Trials (Open as of 12/15/2020)

<table>
<thead>
<tr>
<th>Protocol Number</th>
<th>Phase</th>
<th>Protocol Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>A031102</td>
<td>III</td>
<td>A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors</td>
</tr>
<tr>
<td>A031501</td>
<td>III</td>
<td>Phase III Randomized Adjuvant study of MK-3475 (Pembrolizumab) in muscle invasive and locally advanced urthelial caRcinoma (AMBASSADOR) Versus Observation</td>
</tr>
<tr>
<td>A031701</td>
<td>II</td>
<td>A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (ddGC) in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations</td>
</tr>
<tr>
<td>A031702</td>
<td>II</td>
<td>Phase II Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Rare Genitourinary Tumors</td>
</tr>
<tr>
<td>A031704</td>
<td>III</td>
<td>PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell CancEr (PDIGREE)</td>
</tr>
<tr>
<td>A031801</td>
<td>II</td>
<td>A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients with Advanced Renal Cell Carcinoma with Bone Metastasis (RadCal)</td>
</tr>
<tr>
<td>A031802</td>
<td>II</td>
<td>Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer</td>
</tr>
<tr>
<td>A031901</td>
<td>III</td>
<td>Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A Randomized Phase 3 Non-Inferiority Trial</td>
</tr>
<tr>
<td>AREN1721</td>
<td>II</td>
<td>A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Axitinib or Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups</td>
</tr>
<tr>
<td>EA8134</td>
<td>III</td>
<td>InPACT- International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)</td>
</tr>
<tr>
<td>EA8143</td>
<td>III</td>
<td>A Phase 3 Randomized Study Comparing Perioperative Nivolumab Vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)</td>
</tr>
<tr>
<td>EA8153</td>
<td>II</td>
<td>Cabazitaxel with Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial</td>
</tr>
<tr>
<td>EA8171</td>
<td>II</td>
<td>Multiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer</td>
</tr>
<tr>
<td>EA8183</td>
<td>III</td>
<td>A Phase III Double Blinded Study of Early Intervention After Radical Prostatectomy with Androgen Deprivation Therapy with Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification (ERADICATE)</td>
</tr>
<tr>
<td>EA8185</td>
<td>II</td>
<td>Phase 2 Study of Bladder-Sparing ChemoradiationN with MEDI4736 (Durvalumab) in Clinical Stage 3, Node Positive BladderR CancEr (INSPIRE)</td>
</tr>
<tr>
<td>EA8191</td>
<td>III</td>
<td>Phase III Study of PET-Directed Local or Systemic Therapy Intensification in Prostate Cancer Patients with Post-Prostatectomy Biochemical Recurrence</td>
</tr>
<tr>
<td>NRG-GU002</td>
<td>II/III</td>
<td>Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy with or Without Adjuvant Docetaxel</td>
</tr>
<tr>
<td>NRG-GU005</td>
<td>III</td>
<td>Phase III IGR and SBRT Vs IGR and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer</td>
</tr>
<tr>
<td>NRG-GU007</td>
<td>II</td>
<td>Randomized Phase II Trial of Niraparib with Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (with Initial Phase I)</td>
</tr>
<tr>
<td>NRG-GU008</td>
<td>III</td>
<td>Randomized Phase III Trial Incorporating Abiraterone Acetate with Prednisone and Apalutamide and Advanced Imaging Into Salvage Treatment for Patients with Node-Positive Prostate Cancer After Radical Prostatectomy</td>
</tr>
<tr>
<td>NRG-GU009</td>
<td>III</td>
<td>Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT*)</td>
</tr>
<tr>
<td>S1802</td>
<td>III</td>
<td>Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer</td>
</tr>
<tr>
<td>S1806</td>
<td>III</td>
<td>Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer</td>
</tr>
<tr>
<td>S1931</td>
<td>III</td>
<td>Phase III Trial of Immunotherapy-Based Combination Therapy with or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial)</td>
</tr>
<tr>
<td>EAY131</td>
<td>II</td>
<td>Molecular Analysis for Therapy Choice (MATCH)</td>
</tr>
<tr>
<td>S1609</td>
<td>II</td>
<td>DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors</td>
</tr>
</tbody>
</table>

This portfolio shows NCTN trials. For information about NCORP trials, please see: [https://ncorp.cancer.gov/find-a-study/](https://ncorp.cancer.gov/find-a-study/)